Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Low-Molecular-Weight Heparin Versus Aspirin for Acute Ischemic Stroke with Large Artery Occlusive Disease
Stroke 43:346-349,293, Wang,Q.S,et al, 2012
Low-Molecular-Weight Heparin and Early Neurologic Deterioration in Acute Stroke Caused by Large Artery Occlusive Disease
Arch Neurol 69:1454-1460, Wang, Q.,et al, 2012
Neonatal Cerebral Sinovenous Thrombosis From Symptom to Outcome
Stroke 41:1382-1388, Berfelo,F.J., et al, 2010
Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation
JAMA 293:427-436, The CREATE Trial Group Investigators, 2005
Anticoagulants for Acute Ischemic Stroke
Stroke 35:2916-2917, Sandercock,P.,et al, 2004
Tinzaparin in Acute Ischaemic Stroke (TAIST):A Randomised Aspirin-Controlled Trial
Lancet 358:702-710,683, Bath,P.M.W.,et al, 2001
Low-Molecular-Weight heparins and Heparinoids in Acute ischemic Stroke
Stroke 31:1770-1778, Bath,P.M.W. et al, 2000
Low Molecular Wt Heparinoid
ORG 10172 (Danaparoid) , & Outcome After Acute Ischemic Stroke, 10172 Acute Stroke Trtm (TOAST) Inve, t, JAMA 1272,1304,1998., 1998
Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke
NEJM 333:1588-1593, Kay,R.,et al, 1995